查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1943550

尋常疣治療市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、通路、地區及競爭格局分類，2021-2031年）

Prurigo Nodularis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球結節性癢疹治療市場預計將從 2025 年的 9.7566 億美元成長到 2031 年的 11.6907 億美元，複合年成長率為 3.06%。

針對這種慢性神經免疫疾病的治療策略包括藥物療法，例如局部皮質類固醇、全身性神經調節劑和生物目標，所有這些療法都旨在緩解令人痛苦的搔癢和角化過度病變。該市場的成長主要得益於近期核准的新型單株抗體，這些特異性靶向搔癢通路，與傳統的仿單標示外用藥相比，療效更佳。此外，臨床上對診斷潛在的第二型發炎合併症的日益重視，也進一步擴大了適合接受全身性治療的患者族群。

市場概覽
預測期 2027-2031
市場規模：2025年 9.7566億美元
市場規模：2031年 1,169,070,000 美元
複合年成長率：2026-2031年 3.06%
成長最快的細分市場 皮質類固醇
最大的市場 北美洲

然而，這些先進療法的高昂採集費用構成了一項重大挑戰，並可能限制其在醫療資金有限或報銷政策嚴格的地區的市場滲透。長期堅持用藥以維持療效並預防症狀復發，進一步加劇了這項經濟負擔。例如，2024年，歐洲皮膚病與性病學會報告稱，臨床試驗數據顯示，先前對尼莫利珠單抗治療有效的患者中，停藥後復發率高達75%，這凸顯了持續疾病管理對於維持市場價值至關重要。

市場促進因素

新型生物製藥的商業化正在從根本上改變全球結節性癢疹治療市場，引入核准的標靶治療來取代療效欠佳的仿單標示外用藥。新核准的單株抗體在阻斷搔癢-抓癢循環方面展現出優於傳統免疫抑制劑的卓越能力，隨著這一轉變，其應用率也大幅提升，近期真實世界研究證實了治療效果的持久性。根據賽諾菲在2024年9月歐洲皮膚病學會（EADV）上發表的度普利尤單抗中期分析，50.0%的接受治療患者在6個月時搔癢強度顯著降低。如此高的療效對於應對疾病帶來的巨大負擔至關重要。根據高德美在2024年8月發布的新聞稿，光在美國就有多達18.1萬人受結節性癢疹影響，這為這些已上市的生物製劑創造了龐大的潛在市場。

同時，強大的臨床研發管線和研發投入正在加速市場擴張。這主要得益於兼具高效性和便捷給藥方式的新一代口服小分子藥物的研發競賽。製藥公司正大力投資JAK抑制劑和其他新型給藥途徑，以滿足對注射生物製藥抗藥性或偏好口服給藥的患者的需求。後期臨床試驗結果顯示出改善長期症狀控制的良好跡象。 Incyte公司在2024年9月舉行的歐洲抗病毒藥物研發協會（EADV）年會上公佈的數據顯示，最初對口服45毫克povoltinib有反應的患者中，89%的患者在第40週仍保持療效。這些積極數據支持繼續資金籌措和進行研發，以確保創新療法的穩定供應，從而在未來十年內維持市場價值和競爭力。

市場挑戰

新型藥物療法，尤其是生物目標，其高昂的購買成本是全球結節性癢疹治療市場成長的一大障礙。儘管這些先進治療方法能夠改善臨床療效，但其高昂的價格卻嚴重阻礙了市場滲透，尤其是在醫保報銷機制嚴格、公共醫療資金有限的地區。此外，疾病的慢性病程進一步加劇了這種經濟壓力，患者需要長期接受昂貴的治療方法以防止症狀復發，這不僅加重了支付方的預算負擔，也增加了患者的自付費用。

因此，支付方通常會實施限制性准入通訊協定，從而延緩昂貴治療方法的引入。這種疾病帶來的巨大經濟負擔對市場可近性產生了負面影響。根據2024年國際藥物經濟學與結果研究學會（ISPOR）的數據，真實世界臨床數據顯示，結節性癢疹患者的醫療保健費用顯著高於對照組，每位患者的費用差異高達5736美元。這種日益成長的經濟負擔限制了先進治療方法的應用，最終阻礙了市場的整體獲利能力。

市場趨勢

白細胞介素-31訊號路徑抑制劑的商業性化應用，透過滿足快速緩解症狀的迫切需求，樹立了新的治療標準，使其區別於起效緩慢的頻譜生物製藥。與需要數週才能達到最佳療效的傳統2型發炎抑制劑不同，IL-31拮抗劑直接針對引起搔癢和睡眠障礙的神經通路，從而即時緩解症狀。這正在影響著需要即時穩定生活品質的急性疼痛患者的處方行為。根據高德美公司2025年12月發布的新聞稿，一項3期臨床試驗的事後分析顯示，接受nemolizumab治療的患者中有17.2%在48小時內瘙癢強度顯著降低，而安慰劑組僅為3.7%，這凸顯了該機制在急性症狀管理方面的商業性潛力。

此外，對抑癌素M受體BETA次單元抑制劑的研究代表著治療方法的策略性轉變，即同時針對神經發炎訊號路徑和纖維化組織重塑。這些新型藥物透過抑制抑癌素M受體BETA次單元，阻斷IL-31和抑癌素M細胞激素，從而破壞導致搔癢和結節形成的雙通路，而搔癢和結節正是難治性病例的特徵。這種作用機轉對於僅靠上游免疫調節不足以治療的晚期纖維化病變患者尤其重要。根據Medscape於2025年12月報道，一項隨機IIb期臨床試驗顯示，接受高劑量bicsarelimab治療的患者在第16週時，最嚴重搔癢數字評分量表（Worst Itch Numerical Rating Scale）評分平均降低了56.2%。此結果顯著優於安慰劑組的14.5%的降低幅度，顯示該藥物在治療這種難治性疾病方面具有更優的療效。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球疣治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（皮質類固醇、抗組織胺藥物、潤膚劑、辣椒素乳膏等）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美尋常疣治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲尋常疣治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區尋常疣治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲尋常疣治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲尋常疣治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球尋常疣治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sanofi
  • Regeneron Pharmaceuticals
  • Galderma
  • Amgen
  • Incyte Corporation
  • Novartis
  • LEO Pharma
  • Trevi Therapeutics
  • Kiniksa Pharmaceuticals
  • VYNE Therapeutics

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17525

The Global Prurigo Nodularis Treatment Market is projected to expand from USD 975.66 Million in 2025 to USD 1169.07 Million by 2031, registering a compound annual growth rate (CAGR) of 3.06%. Treatment strategies for this chronic neuroimmune condition involve pharmacotherapeutic interventions such as topical corticosteroids, systemic neuromodulators, and targeted biologics, all aimed at mitigating debilitating pruritus and hyperkeratotic lesions. The market is primarily propelled by recent regulatory approvals of novel monoclonal antibodies that specifically target itch pathways, providing enhanced efficacy compared to traditional off-label agents, while a growing clinical emphasis on diagnosing underlying type 2 inflammatory comorbidities further enlarges the patient population eligible for systemic intervention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 975.66 Million
Market Size 2031USD 1169.07 Million
CAGR 2026-20313.06%
Fastest Growing SegmentCorticosteroids
Largest MarketNorth America

However, the substantial acquisition costs associated with these advanced therapies pose a major challenge, potentially restricting market penetration in regions with limited healthcare funding or strict reimbursement policies. This financial burden is exacerbated by the need for long-term adherence to maintain therapeutic benefits and prevent symptom recurrence. For instance, the European Academy of Dermatology and Venereology reported in 2024 that clinical trial data indicated a 75% relapse rate among prior responders who discontinued nemolizumab treatment, underscoring the critical necessity for continuous disease management to sustain market value.

Market Driver

The commercialization of novel biologic therapies is fundamentally transforming the Global Prurigo Nodularis Treatment Market by introducing approved, targeted interventions that supersede less effective off-label options. Adoption rates are surging as newly authorized monoclonal antibodies demonstrate a superior ability to disrupt the itch-scratch cycle compared to traditional immunosuppressants, a shift supported by recent real-world evidence of therapeutic durability. As noted by Sanofi in September 2024 during the EADV Congress, an interim analysis of Dupilumab usage revealed that 50.0% of treated patients achieved a clinically meaningful reduction in itch intensity at six months; this high efficacy is essential for addressing the significant disease burden, which Galderma's August 2024 press release estimates affects up to 181,000 individuals in the United States alone, representing a vast addressable market for these commercialized biologics.

Simultaneously, robust clinical pipelines and R&D investments are accelerating market expansion, driven by a race to develop next-generation oral small molecules that combine high efficacy with convenient administration. Pharmaceutical companies are heavily investing in JAK inhibitors and other novel pathways to serve patients who may be refractory to injectable biologics or prefer oral dosing, with late-stage results showing promise for improved long-term control. According to Incyte's presentation at the September 2024 EADV Congress, 89% of patients who initially responded to a 45 mg dose of oral povorcitinib maintained their response through week 40, positive data that incentivizes continued funding and development to ensure a steady stream of innovative therapies capable of sustaining market value and competition over the coming decade.

Market Challenge

The high acquisition costs linked to novel pharmacotherapeutic interventions, particularly targeted biologics, constitute a significant barrier to the growth of the Global Prurigo Nodularis Treatment Market. Although these advanced therapies deliver improved clinical outcomes, their substantial pricing creates considerable hurdles for market penetration, especially in regions with stringent reimbursement frameworks or limited public healthcare funds. This financial pressure is compounded by the chronic nature of the disease, which requires long-term adherence to expensive regimens to prevent symptom recurrence, thereby straining payer budgets and increasing out-of-pocket expenses for patients.

As a result, payers often enforce restrictive access protocols that delay the uptake of premium treatments, negatively impacting market accessibility due to the substantial economic weight of the condition. According to data from the International Society for Pharmacoeconomics and Outcomes Research in 2024, real-world evidence revealed that patients with Prurigo Nodularis incurred significantly higher healthcare costs, with a difference of $5,736 per patient compared to matched controls. This elevated economic burden limits the widespread adoption of advanced therapies, subsequently hampering the overall revenue potential of the market.

Market Trends

The commercial adoption of Interleukin-31 signaling inhibitors is establishing a new standard of care by addressing the critical need for rapid symptom relief, distinguishing these therapies from slower-acting broad-spectrum biologics. Unlike traditional type 2 inflammation blockers that may take weeks to show optimal benefits, IL-31 antagonists directly target the neuronal pathways responsible for the immediate sensation of itch and sleep disruption, influencing prescribing behaviors for patients in acute distress who require immediate stabilization of their quality of life. According to a December 2025 press release from Galderma, post-hoc analysis of Phase III trials showed that 17.2% of patients treated with nemolizumab achieved a significant reduction in itch intensity within just 48 hours compared to only 3.7% in the placebo group, highlighting the commercial potential of this mechanism for acute symptom management.

Additionally, the investigation of Oncostatin M receptor beta blockers represents a strategic shift toward therapies that simultaneously target neuro-inflammatory signaling and fibrotic tissue remodeling. By inhibiting the beta subunit of the oncostatin M receptor, these novel agents block both IL-31 and oncostatin M cytokines, disrupting the dual pathways of pruritus and nodule formation that characterize refractory cases. This mechanism is particularly relevant for patients with highly fibrotic lesions who may not respond adequately to upstream immune modulation alone; as reported by Medscape in December 2025, a Phase 2b randomized trial demonstrated that high-dose vixarelimab resulted in a 56.2% decrease in mean Worst Itch-Numeric Rating Scale scores at week 16, significantly outperforming the 14.5% reduction in the placebo group and suggesting superior efficacy for difficult-to-treat phenotypes.

Key Market Players

  • Sanofi
  • Regeneron Pharmaceuticals
  • Galderma
  • Amgen
  • Incyte Corporation
  • Novartis
  • LEO Pharma
  • Trevi Therapeutics
  • Kiniksa Pharmaceuticals
  • VYNE Therapeutics

Report Scope

In this report, the Global Prurigo Nodularis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prurigo Nodularis Treatment Market, By Product

  • Corticosteroids
  • Anti-Histamines
  • Emollients
  • Capsaicin Cream
  • Others

Prurigo Nodularis Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Prurigo Nodularis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prurigo Nodularis Treatment Market.

Available Customizations:

Global Prurigo Nodularis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prurigo Nodularis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Corticosteroids, Anti-Histamines, Emollients, Capsaicin Cream, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Prurigo Nodularis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prurigo Nodularis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Prurigo Nodularis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Prurigo Nodularis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Prurigo Nodularis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prurigo Nodularis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Prurigo Nodularis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Prurigo Nodularis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Prurigo Nodularis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Prurigo Nodularis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Prurigo Nodularis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prurigo Nodularis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Prurigo Nodularis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Prurigo Nodularis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Prurigo Nodularis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Prurigo Nodularis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Prurigo Nodularis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prurigo Nodularis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Prurigo Nodularis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Prurigo Nodularis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Prurigo Nodularis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prurigo Nodularis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Prurigo Nodularis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Prurigo Nodularis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prurigo Nodularis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Regeneron Pharmaceuticals
  • 15.3. Galderma
  • 15.4. Amgen
  • 15.5. Incyte Corporation
  • 15.6. Novartis
  • 15.7. LEO Pharma
  • 15.8. Trevi Therapeutics
  • 15.9. Kiniksa Pharmaceuticals
  • 15.10. VYNE Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer